XLV The Health Care Select Sector SPDR® Fund
- 156.160
- +0.320+0.21%
Do Queasy Side Effects Mean the End of Weight-loss Drug Stock Hype?
Least Shorted S&P 500 Stocks in August
Executive Reshuffles: LLY, S and RY Companies in Focus
J&J Leads H1 Healthcare Deals as Big Pharma Dealmaking Returns: Report
Merck Keytruda With Eisai's Lenvima Succeeds in Late-stage Trial for Liver Cancer
Trending Stocks This Week as Market Bounces Back From Selloff
Merck Keytruda Cuts Mortality Risk in Gastric Cancer by 20%
GSK, ITeos Lung Cancer Therapy Outperforms Jemperli in Mid-stage Trial
S&P Soars to Best Week of 2024 as Wall Street Gears up for Anticipated Interest Rate Cuts
Moderna Faces Analyst Downgrades Amid Revised R&D Restructured Strategy and Delayed Profitability Target
Arcus up 4% Following Merck Welireg Kidney Cancer Data
Merck & Co Unusual Options Activity
Summit Boosts Instil, BioNTech as Lead Drug Beats Merck's Keytruda
Catalyst Watch: FOMC, FedEx Earnings, Electronic Arts Event, and Triple Witching Day
Merck Goes Ex Dividend Monday
Moderna Continues to Decline as Oppenheimer Latest to Downgrade
Eli Lilly Analyst Ratings
How do you view the recent "hawkish" stance of the Bank of Japan executives? Goldman Sachs: The next interest rate hike may still have to wait until January next year.
Goldman Sachs believes that when evaluating the timing of interest rate hikes, it is important to consider financial market stability and inflation trends. The bank predicts that January next year will be the best time to determine whether Japan's inflation will rebound, and based on this, determine that Japan will raise interest rates in January. However, if there is significant turmoil in the financial markets, the timing of the rate hike may become uncertain.
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday as Investors Await Import, Export Data
Moderna Extends Losses as R&D Day Updates Lead to Downgrades